Transcode Therapeutics, Inc. financial data

Symbol
RNAZ on Nasdaq
Industry
Pharmaceutical Preparations
Location
6 Liberty Square, #2382, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Apr 15, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 194 % +51.6%
Debt-to-equity 321 % +34.7%
Return On Equity -1.21K % -29.4%
Return On Assets -287 % -3.98%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23.3M shares +302%
Common Stock, Shares, Outstanding 1.03M shares +5312%
Entity Public Float 7.3M USD +65.9%
Common Stock, Value, Issued 103 USD +5050%
Weighted Average Number of Shares Outstanding, Basic 356K shares -93.4%
Weighted Average Number of Shares Outstanding, Diluted 356K shares -93.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.71M USD -20.9%
General and Administrative Expense 5.95M USD -16.8%
Operating Income (Loss) -15.7M USD +19.4%
Nonoperating Income (Expense) -1.09M USD -225%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -16.8M USD +9.66%
Earnings Per Share, Basic -47.1 USD/shares
Earnings Per Share, Diluted -47.1 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.81M USD +110%
Assets, Current 7.09M USD +59.2%
Property, Plant and Equipment, Net 51.6K USD -57.3%
Operating Lease, Right-of-Use Asset 37.7K USD -92.2%
Assets 7.29M USD +41.1%
Contract with Customer, Liability, Current 25.4K USD -6.1%
Liabilities, Current 2.77M USD -20.6%
Operating Lease, Liability, Noncurrent 38.3K USD
Liabilities 9.31M USD +164%
Retained Earnings (Accumulated Deficit) -63.2M USD -36.2%
Stockholders' Equity Attributable to Parent -2.02M USD -223%
Liabilities and Equity 7.29M USD +41.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.94M USD +12.8%
Net Cash Provided by (Used in) Financing Activities 6.09M USD +416%
Net Cash Provided by (Used in) Investing Activities -3.84K USD +70.3%
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 1.03M shares +5312%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.15M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.81M USD +110%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.65K USD -31.9%
Deferred Tax Assets, Valuation Allowance 16.1M USD +27.4%
Deferred Tax Assets, Gross 16.1M USD +27.4%
Operating Lease, Liability 38.3K USD -91.5%
Depreciation 32.2K USD +8.52%
Payments to Acquire Property, Plant, and Equipment 3.84K USD -70.3%
Lessee, Operating Lease, Liability, to be Paid 38.3K USD -91.7%
Property, Plant and Equipment, Gross 362K USD -5.64%
Operating Lease, Liability, Current 38.3K USD -90.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD -90.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.03K USD -93.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.89M USD +51.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 228K USD -35.4%
Operating Lease, Payments 412K USD -28.4%
Additional Paid in Capital 61.2M USD +27.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 90.9K USD -26.4%
Interest Expense 26.8K USD -52%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%